Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion type Assertion NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_head.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion description "[These findings reveal the increased risks of cancer metastasis and chemoresistance by applying Cox-2 inhibitors, celecoxib in particular, in clinical trials of NSCLC treatment and urge intensive preclinical assessment before proceeding to clinical application.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_provenance.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion evidence source_evidence_literature NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_provenance.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion SIO_000772 23172668 NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_provenance.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion wasDerivedFrom befree-2016 NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_provenance.
- NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_assertion wasGeneratedBy ECO_0000203 NP1030270.RAAZ7qGfbxqyx3EZY_u6EbB0i224tt-bLaT6n9x5ncf_s130_provenance.